TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6527752

Group type: EXPERIMENTAL
Intervention: disulfiram (400 mg/day) for 6 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo tablets
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: propranolol (80 mg/day) for 4 weeks
Number of subjects: 8
Study: 30510410

Group type: EXPERIMENTAL
Intervention: Better living with COPD (intervention)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 182
Study: 27730283

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen (HFNC) combined with non-invasive ventilation (NIV)
Number of subjects: 49

Group type: COMPARATOR
Intervention: NIV alone
Number of subjects: 49
Study: 24617598

Group type: EXPERIMENTAL
Intervention: Therapeutic kinesio taping with tension
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham kinesio taping without tension
Number of subjects: 40
Study: 23078797

Group type: EXPERIMENTAL
Intervention: Personal tailored letter with risk information and invitation to a taster session
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Standard generic letter advertising the local service
Number of subjects: 4500
Study: 21134041

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (2 U/0.1 mL; 30 facial injections on half of the face, each 0.1 mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline (30 facial injections on half of the face, each 0.1 mL)
Number of subjects: 10
Study: 17641457

Group type: EXPERIMENTAL
Intervention: Red paper
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blue paper
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red and Blue conditions
Number of subjects: 0
Study: 15655139

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of efalizumab weekly
Number of subjects: 556

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 556
Study: 12174532

Group type: EXPERIMENTAL
Intervention: High-efficacy condition
Number of subjects: 59

Group type: COMPARATOR
Intervention: Low-efficacy condition
Number of subjects: 59
Study: 9924155

Group type: EXPERIMENTAL
Intervention: Percutaneous revascularization procedures for patients with unstable angina with electrocardiographic changes
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Percutaneous revascularization procedures for patients with rest chest pain
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Atherectomy
Number of subjects: 1010
Study: 7751072

Group type: EXPERIMENTAL
Intervention: Liquid carbohydrate feeding (F)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Semi-solid carbohydrate feeding (S)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Liquid placebo (P)
Number of subjects: 32
Study: 2255352

Group type: EXPERIMENTAL
Intervention: External version
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: External version with tocolysis
Number of subjects: 52

Group type: COMPARATOR
Intervention: Initial attempts without tocolysis
Number of subjects: 52
Study: 6969348

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole and lactobacilli preparation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Framycetin, colymycin, nystatin, and metronidazole
Number of subjects: 68
Study: 30446826

Group type: EXPERIMENTAL
Intervention: Three PVB injections
Number of subjects: 200

Group type: COMPARATOR
Intervention: Five PVB injections
Number of subjects: 200
Study: 28476487

Group type: EXPERIMENTAL
Intervention: Menopur® - Ferring
Number of subjects: 270

Group type: COMPARATOR
Intervention: Meriofert® - IBSA Institut Biochimique SA
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Menopur® - Ferring and Meriofert® - IBSA Institut Biochimique SA
Number of subjects: 270
Study: 26026936

Group type: EXPERIMENTAL
Intervention: A1PI (α1 proteinase inhibitor) intravenously 60 mg/kg per week for 24 months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 180
Study: 23329651

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 100
Study: 21346517

Group type: EXPERIMENTAL
Intervention: music and art therapy and psychomotor activity
Number of subjects: 146

Group type: COMPARATOR
Intervention: free activities in the day room
Number of subjects: 146
Study: 19750958

Group type: EXPERIMENTAL
Intervention: Multilevel dietary intervention
Number of subjects: 2175

Group type: COMPARATOR
Intervention: Comparison ROs (Control)
Number of subjects: 2175
Study: 17584552

Group type: EXPERIMENTAL
Intervention: ECG timing method
Number of subjects: 175

Group type: COMPARATOR
Intervention: Historical timing
Number of subjects: 175
Study: 15171765

Group type: EXPERIMENTAL
Intervention: Nonablative skin remodeling with a 1540-nm Er:Glass laser
Number of subjects: 20
Study: 11798458

Group type: EXPERIMENTAL
Intervention: Single dose of consensus interferon (IFN-con1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous treatment with consensus interferon (IFN-con1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline IL-6 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in IL-6 levels
Number of subjects: 0
Study: 9716140

Group type: EXPERIMENTAL
Intervention: PLA2 polymorphism
Number of subjects: 114

Group type: COMPARATOR
Intervention: PLA polymorphisms
Number of subjects: 114
Study: 9252796

Group type: EXPERIMENTAL
Intervention: Pizotifen and sumatriptan
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo prophylaxis and sumatriptan
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sumatriptan alone
Number of subjects: 88
Study: 1959364

Group type: EXPERIMENTAL
Intervention: APACHE II score (low score <= 9)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: APACHE II score (high score >= 25)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Score (normal score 14 to 15)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Score (low score 3)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Acute Physiology Score model
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Score model
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 604
Study: 7077615

Group type: EXPERIMENTAL
Intervention: Power-frequency (50 Hz) electric fields up to an intensity of 20 kV/m
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study: 30971225

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg/day, 4 × 40 mg capsules once daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Flutamide (375 mg/day; 3 × 125 mg tablets thrice daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Flutamide
Number of subjects: 100
Study: 28849310

Group type: EXPERIMENTAL
Intervention: TTFields with temozolomide (n=210)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Temozolomide alone (n=105)
Number of subjects: 315
Study: 26074395

Group type: EXPERIMENTAL
Intervention: Pazopanib 800mg/day
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 25149587

Group type: EXPERIMENTAL
Intervention: Flow Controlled Expiration (FLEX)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Positive End Expiratory Pressure (PEEP=0, 3, 6 or 9 cmH2O)
Number of subjects: 24
Study: 23077043

Group type: EXPERIMENTAL
Intervention: fMRI adaptation with repeated presentations of an object near the hand for different arm postures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived ownership of a prosthetic hand during an illusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peri-hand space remapping in the premotor cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peri-hand space remapping in the posterior parietal cortex
Number of subjects: 0
Study: 19387330

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (30 ng/kg/min)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline + LPS (2 ng/kg)
Number of subjects: 17
Study: 17250535

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.005 mg/mL
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05 mg/mL
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.5 mg/mL
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 10
Study: 15047241

Group type: EXPERIMENTAL
Intervention: Liposomal lurtotecan at a dose of 2.4 mg/m(2) on Days 1 and 8 of a 21-day cycle
Number of subjects: 22
Study: 12477021

Group type: EXPERIMENTAL
Intervention: Reichert AT550 non-contact tonometer
Number of subjects: 35

Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 35

Group type: COMPARATOR
Intervention: Reichert Xpert Plus
Number of subjects: 35

Group type: COMPARATOR
Intervention: Perkins tonometer
Number of subjects: 35
Study: 9096985

Group type: EXPERIMENTAL
Intervention: 250 mg b.i.d. BTS 67,582
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 500 mg b.i.d. BTS 67,582
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 500 mg q.d. BTS 67,582
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8256475

Group type: EXPERIMENTAL
Intervention: Body acupuncture with electric needles (10 Hz, current titrated to individual threshold, 25 min each session) on acupuncture points Di4 [He Gu], Ma25 [Tian Shu], Le3 [Yuan], and B125 [Da Chang Yu]
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Body acupuncture with electric needles
Number of subjects: 8
Study: 3515923

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (Ansaid, Upjohn)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurbiprofen plus etidocaine (long‐acting local anesthetic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen alone or in combination with oxycodone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen/oxycodone and lidocaine
Number of subjects: 0
Study: 31133457

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (conventional subcutaneous insulin therapy)
Number of subjects: 0
Study: 30387043

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 400-1200 mg/day
Number of subjects: 72
Study: 26934620

Group type: EXPERIMENTAL
Intervention: Walking intervention
Number of subjects: 229

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 229
Study: 24661523

Group type: EXPERIMENTAL
Intervention: Calf pulmonary surfactant (50 mg/kg) within 6 hours after admission (Treatment group 1)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Calf pulmonary surfactant (70 mg/kg) within 6 hours after admission (Treatment group 2)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (no PS within 6 hours after admission, PS (50 mg/kg) given later if no remission)
Number of subjects: 175
Study: 22971501

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 100
Study: 20453654

Group type: EXPERIMENTAL
Intervention: Fujinon Intelligent Color Enhancement (FICE) with magnification
Number of subjects: 144

Group type: COMPARATOR
Intervention: Indigo carmine dye with magnification
Number of subjects: 144
Study: 18819261

Group type: EXPERIMENTAL
Intervention: Nifekalant hydrochloride (NIFE) administration after ICD shock
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no NIFE administration)
Number of subjects: 25
Study: 16115099

Group type: EXPERIMENTAL
Intervention: Hydatid fluid (100 microg in 100 microl of PBS with FCA)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Protoscolex proteins (100 microg in 100 microl of PBS with FCA)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Whole body protein of E. granulosus (1 mg in 2 ml of PBS with FCA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Adjuvant in PBS (control for mice)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Adjuvant in PBS (control for sheep)
Number of subjects: 23
Study: 11954900

Group type: EXPERIMENTAL
Intervention: Controlled-release formulations (oral and transdermal) for steady pain management and fast-acting, immediate-release formulations for breakthrough pain management.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized opioid treatment based on drug absorption, metabolism, toxicity, and binding characteristics.
Number of subjects: 0
Study: 10348790

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 14C-labeled tacrolimus (0.01 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral administration of 14C-labeled tacrolimus (0.05 mg/kg)
Number of subjects: 6
Study: 8600865

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rH‐EPO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EPO vehicle (Control)
Number of subjects: 0
Study: 2064859

Group type: EXPERIMENTAL
Intervention: 2% lignocaine containing 1:80,000 adrenaline (Xylocaine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3% prilocaine with 0.03 IU/ml felypressin (Citanest)
Number of subjects: 20
Study: 6844301

Group type: EXPERIMENTAL
Intervention: Individual treatment with advice for cholesterol lowering diet, smoking cessation, regular exercise, weight reduction, and drug control of hypertension for high-risk individuals; mass education for non-high-risk individuals.
Number of subjects: 63000

Group type: COMPARATOR
Intervention: Control group receiving no individual treatment, only mass education for non-high-risk individuals.
Number of subjects: 63000
Study: 31596444

Group type: EXPERIMENTAL
Intervention: Low-dose, low-frequency oral psoralen-UV-A treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29698965

Group type: EXPERIMENTAL
Intervention: Nocturia group (45 men)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (21 men)
Number of subjects: 138
Study: 27267880

Group type: EXPERIMENTAL
Intervention: Low-dose rotigotine (≤6 mg/24 h for early PD or ≤8 mg/24 h for advanced PD)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: High-dose rotigotine (≤8 mg/24 h for early PD or ≤16 mg/24 h for advanced PD)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Low-dose rotigotine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: High-dose rotigotine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 24798657

Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Carvedilol 20 mg
Number of subjects: 11
Study: 23057765

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bovine milk
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Reconstituted bovine whey protein
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Reconstituted bovine casein protein
Number of subjects: 9

Group type: COMPARATOR
Intervention: White wheat bread (WWB)
Number of subjects: 9
Study: 20588292

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD)
Number of subjects: 932
Study: 17380117

Group type: EXPERIMENTAL
Intervention: Narrowband UVB (TL‐01 lamps)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Selective broadband UVB (UV6 lamps)
Number of subjects: 100
Study: 15627448

Group type: EXPERIMENTAL
Intervention: Myringotomy with oral antibiotics (Group A)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Oral antibiotics without myringotomy (Group B)
Number of subjects: 59
Study: 11978141

Group type: EXPERIMENTAL
Intervention: 40% urea cream (Carmol 40)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 12% ammonium lactate lotion (Lac‐Hydrin 12%)
Number of subjects: 25
Study: 9615361

Group type: EXPERIMENTAL
Intervention: Progressive idiopathic scoliosis
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Nonprogressive idiopathic scoliosis
Number of subjects: 146

Group type: COMPARATOR
Intervention: Healthy adolescent girls (control group)
Number of subjects: 146
Study: 8594399

Group type: EXPERIMENTAL
Intervention: Read-write tutorial version
Number of subjects: 0

Group type: COMPARATOR
Intervention: Read-only tutorial version
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both software versions (read-only and read-write)
Number of subjects: 0
Study: 2642440

Group type: EXPERIMENTAL
Intervention: Combination of 5 mg/kg CDC plus 5 mg/kg UDC
Number of subjects: 120

Group type: COMPARATOR
Intervention: UDC alone (10 mg/kg)
Number of subjects: 120
Study: 4850208

Group type: EXPERIMENTAL
Intervention: Truncal vagotomy and drainage (V-D)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Truncal vagotomy and antrectomy (V-R)
Number of subjects: 200
Study: 30790028

Group type: EXPERIMENTAL
Intervention: Palliative care-led meetings
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Negative perception of patient’s physical comfort and emotional support
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Surrogate perception that clinicians did not listen to concerns
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Failure of the physician to explain how the patient’s pain would be treated
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Lack of sufficient religious contact
Number of subjects: 306
Study: 28653458

Group type: EXPERIMENTAL
Intervention: LV-only pacing
Number of subjects: 161

Group type: COMPARATOR
Intervention: Biventricular pacing
Number of subjects: 161
Study: 25639289

Group type: EXPERIMENTAL
Intervention: Acupuncture (2 times per week for 5 weeks, total of 10 sessions)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 36
Study: 23303614

Group type: EXPERIMENTAL
Intervention: Normal BMI group (BMI 20-25)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Overweight group (BMI > 25)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 20350135

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: DRD2/ANKK1 genotype (TT vs CC)
Number of subjects: 577
Study: 18304675

Group type: EXPERIMENTAL
Intervention: Insulin Aspart 0.08 IU/kg BW 30 min before meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin Aspart 0.04 IU/kg BW 30 min before meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin Aspart 0.04 IU/kg BW 15 min before meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16006728

Group type: EXPERIMENTAL
Intervention: Prophylactic L-thyroxine treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Follow-up without treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 12440503

Group type: EXPERIMENTAL
Intervention: Osteoset pellets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (defect left empty)
Number of subjects: 20
Study: 10511942

Group type: EXPERIMENTAL
Intervention: Tranilast 0.5% eyedrops, administered 4 times a day for 3 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo eyedrops, administered 4 times a day for 3 months
Number of subjects: 35
Study: 8622101

Group type: EXPERIMENTAL
Intervention: Isepamicin 15 mg/kg once daily + ceftazidime 2g twice daily
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Isepamicin 8 mg/kg once daily + ceftazidime 1g twice daily
Number of subjects: 177

Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily + ceftazidime 2g twice daily
Number of subjects: 177

Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily + ceftazidime 1g twice daily
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Isepamicin
Number of subjects: 177

Group type: COMPARATOR
Intervention: Isepamicin and Amikacin
Number of subjects: 177
Study: 2290023

Group type: EXPERIMENTAL
Intervention: Oral adjuvant (taurine) with HBV vaccine
Number of subjects: 86

Group type: COMPARATOR
Intervention: HBV vaccine alone (no adjuvant)
Number of subjects: 86
Study: 7299507

Group type: EXPERIMENTAL
Intervention: 525 mg of ferrous sulfate (105 mg elemental iron) and 500 mg ascorbic acid
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 29510372

Group type: EXPERIMENTAL
Intervention: Daily fiber intake during an 18-month weight loss intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline fiber intake
Number of subjects: 0
Study: 27325862

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide and methotrexate maintenance (cyclophosphamide 50 mg/day orally continuously and methotrexate 2.5 mg twice/day orally on days 1 and 2 of every week for 1 year)
Number of subjects: 1086

Group type: COMPARATOR
Intervention: No CM
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide and methotrexate maintenance
Number of subjects: 1086
Study: 24225325

Group type: EXPERIMENTAL
Intervention: NRP-e (nurse-led email reminder program)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (usual CVD prevention and educational program)
Number of subjects: 198
Study: 22172000

Group type: EXPERIMENTAL
Intervention: Evaluation funded group (provided funding for compression bandaging and medical footwear)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Multilayer bandaging (received by those with confirmed diagnosis, irrespective of group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Evaluation funded group
Number of subjects: 120
Study: 20860238

Group type: EXPERIMENTAL
Intervention: Bilateral Internal Sphincterotomy (BIS) at 3 and 9 o'clock
Number of subjects: 211

Group type: COMPARATOR
Intervention: Unilateral Internal Sphincterotomy (UIS) at 3 o'clock
Number of subjects: 211
Study: 18296421

Group type: EXPERIMENTAL
Intervention: 1-year trastuzumab treatment
Number of subjects: 3401

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3401
Study: 15756004

Group type: EXPERIMENTAL
Intervention: IL-6 levels less than or equal to the median (4.80 pg/mL)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: IL-6 levels above the median (4.80 pg/mL)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: IL-6 levels at a cut point of 13.31 pg/mL
Number of subjects: 191
Study: 14507747

Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo (as vehicle)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Levocabastine hydrochloride 0.05% ophthalmic suspension
Number of subjects: 519
Study: 10593380

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 139
Study: 8944829

Group type: EXPERIMENTAL
Intervention: Intra-arterially administered losartan (100-3000 ng/kg/min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Orally administered losartan (50 mg once daily for 5 days)
Number of subjects: 24